Stay updated with breaking news from Nasdaq Labp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Landos Biopharma, Inc. (NASDAQ:LABP – Get Rating) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 208,400 shares, a growth of 23.8% from the February 13th total of 168,400 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average […]
Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND...
Landos Biopharma Announces Pricing of Initial Public Offering February 03, 2021 20:13 ET | Source: Landos Biopharma, Inc. Landos Biopharma, Inc. Blacksburg, Virginia, UNITED STATES BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross pro...